451 related articles for article (PubMed ID: 29702293)
1. Incidence of Hepatitis B Virus Reactivation and Hepatotoxicity in Patients Receiving Long-term Treatment With Tumor Necrosis Factor Antagonists.
Pauly MP; Tucker LY; Szpakowski JL; Ready JB; Baer D; Hwang J; Lok AS
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1964-1973.e1. PubMed ID: 29702293
[TBL] [Abstract][Full Text] [Related]
2. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
[TBL] [Abstract][Full Text] [Related]
3. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts.
Tamori A; Koike T; Goto H; Wakitani S; Tada M; Morikawa H; Enomoto M; Inaba M; Nakatani T; Hino M; Kawada N
J Gastroenterol; 2011 Apr; 46(4):556-64. PubMed ID: 21246383
[TBL] [Abstract][Full Text] [Related]
4. Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-α therapy.
Fidan S; Capkın E; Arıca DA; Durak S; Okatan IE
Int J Rheum Dis; 2021 Feb; 24(2):254-259. PubMed ID: 33244900
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
Su YC; Lin PC; Yu HC; Wu CC
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):925-929. PubMed ID: 29621049
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy.
Lee YH; Bae SC; Song GG
Clin Exp Rheumatol; 2013; 31(1):118-21. PubMed ID: 23111095
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation.
Yoo JJ; Cho EJ; Cho YY; Lee M; Lee DH; Cho Y; Lee JH; Yu SJ; Yoon SS; Yoon JH; Kim YJ
Liver Int; 2015 Dec; 35(12):2530-6. PubMed ID: 26053357
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs.
Lee YH; Bae SC; Song GG
Int J Rheum Dis; 2013 Oct; 16(5):527-31. PubMed ID: 24164839
[TBL] [Abstract][Full Text] [Related]
10. Long-term use of methotrexate does not result in hepatitis B reactivation in rheumatologic patients.
Laohapand C; Arromdee E; Tanwandee T
Hepatol Int; 2015 Apr; 9(2):202-8. PubMed ID: 25788188
[TBL] [Abstract][Full Text] [Related]
11. Patients with core antibody positive and surface antigen negative Hepatitis B (anti-HBc+, HBsAg-) on anti-TNF therapy have a low rate of reactivation.
Clarke WT; Amin SS; Papamichael K; Feuerstein JD; Cheifetz AS
Clin Immunol; 2018 Jun; 191():59-62. PubMed ID: 29601854
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.
Papadopoulos N; Deutsch M; Manolakopoulos S; Bitsi C; Michalakeas H; Poulakidas H; Tsironi E; Giannouli S; Papatheodoridis GV; Koskinas J; Pectasides D
Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):56-60. PubMed ID: 27669175
[TBL] [Abstract][Full Text] [Related]
13. Early Hepatitis B Surface Antigen Seroclearance Following Antiviral Treatment in Patients with Reactivation of Resolved Hepatitis B.
Lee HL; Jang JW; Han JW; Lee SW; Bae SH; Choi JY; Han NI; Yoon SK; Kim HJ; Lee S; Cho SG; Min CK; Kim DW; Lee JW
Dig Dis Sci; 2019 Oct; 64(10):2992-3000. PubMed ID: 30982209
[TBL] [Abstract][Full Text] [Related]
14. Commensurate incidence and outcomes of liver enzyme elevation between anti-tumor necrosis factor users with or without prior hepatitis B virus infections.
Chiu YM; Lai MS; Chan KA
PLoS One; 2018; 13(4):e0196210. PubMed ID: 29694398
[TBL] [Abstract][Full Text] [Related]
15. Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies.
Biondo MI; Germano V; Pietrosanti M; Canzoni M; Marignani M; Stroffolini T; Salemi S; D'Amelio R
Eur J Intern Med; 2014 Jun; 25(5):482-4. PubMed ID: 24495663
[TBL] [Abstract][Full Text] [Related]
16. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.
Ji D; Cao J; Hong X; Li J; Wang J; Chen F; Wang C; Zou S
Eur J Haematol; 2010 Sep; 85(3):243-50. PubMed ID: 20491883
[TBL] [Abstract][Full Text] [Related]
17. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
Chen FW; Coyle L; Jones BE; Pattullo V
Liver Int; 2013 Sep; 33(8):1203-10. PubMed ID: 23522150
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B virus reactivation by immunosuppressive therapy in patients with autoimmune diseases: risk analysis in Hepatitis B surface antigen-negative cases.
Kato M; Atsumi T; Kurita T; Odani T; Fujieda Y; Otomo K; Horita T; Yasuda S; Koike T
J Rheumatol; 2011 Oct; 38(10):2209-14. PubMed ID: 21844146
[TBL] [Abstract][Full Text] [Related]
19. A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection.
Salpini R; Battisti A; Colagrossi L; Di Carlo D; Fabeni L; Piermatteo L; Cerva C; Lichtner M; Mastroianni C; Marignani M; Maylin S; Delaugerre C; Morisco F; Coppola N; Marrone A; Angelico M; Sarmati L; Andreoni M; Perno CF; Ceccherini-Silberstein F; Svicher V
J Viral Hepat; 2019 Jul; 26(7):846-855. PubMed ID: 30974483
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice.
Loggi E; Gitto S; Galli S; Minichiello M; Conti F; Grandini E; Scuteri A; Vitale G; Di Donato R; Cursaro C; Furlini G; Andreone P
J Clin Virol; 2017 Aug; 93():66-70. PubMed ID: 28654775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]